Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to reflect a new version of the study, with the addition of collaborators and a specific study identifier, while significant details about the study's objectives and inclusion/exclusion criteria have been removed.SummaryDifference19%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference2%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check110 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.